2023-11-15T12:58:46-06:00 2022-12-31 FORVIS LLP 8200 W Interstate 10 Suite 900 San Antonio TX 782303806 990 2022-01-01 462216869 GENCURE % BENJAMIN LOPEZ GENC 2107579505 6211 IH 10 WEST SAN ANTONIO TX 78201 JOHN YOUNGDAHL SVP, CFO 2107579505 2023-11-15 true JOHN YOUNGDAHL 999009999 Roberto Ulloa P01953132 2103419400 2023-11-15 3 2022 2023-04-26 12:10:37Z MARTIN J LANDON 6211 IH 10 WEST SAN ANTONIO TX 78201 5012409 false X WWW.GENCURE.ORG X 2013 TX SEE SCHEDULE O 1 0 38 0 0 0 0 0 3310880 4996591 0 0 679927 15818 3990807 5012409 0 0 0 0 3022407 3435544 0 0 0 7616322 10285479 10638729 13721023 -6647922 -8708614 16636977 21827142 10390071 14793055 6246906 7034087 X GENCURE IS ORGANIZED TO FOCUS ON REGENERATIVE MEDICINE AND THE UTILIZATION OF THE POWER OF HUMAN CELLS AND TISSUE TO ENHANCE LIVES AND ENABLE CLINICAL ADVANCEMENTS. false false 9384129 5012409 SEE SCHEDULE O 9384129 true false false true false false false false false false true false false true true false true true false false false false false false false false false false false true false false false false false false false false false false false false false true true true false false true 10 0 true 38 true false false false false false false false false false false false false X 1 0 false false false false true false false true true false false false true true true true true false false false X BENJAMIN LOPEZ 2107579505 6211 IH 10 WEST SAN ANTONIO TX 78201 X BECKY CAP SVP COO, GENCURE (THRU 09/22) 49.0 1.0 X 237559 49976 15230 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS 50.0 0.0 X 228727 0 28113 ROGELIO ZAMILPA SR. DIRECTOR, MFG SCIENCES 50.0 0.0 X 190189 0 28704 CHRISTIE ELAINE MALONE DIRECTOR, BUSINESS DEVELOPMENT 50.0 0.0 X 166785 0 29822 MARI LANE SALMI SR. DIRECTOR PROCESS DEV & CEL 50.0 0.0 X 138468 0 35202 AMANDA THERESE WHITELONIS DIRECTOR, PROGRAM MANAGEMENT 50.0 0.0 X 147126 0 17737 KATHRYN ANN MILLAR SR SCIENTIFIC AND SALES SPECIA 50.0 0.0 X 135210 0 8544 BIOBRIDGE GLOBAL SOLE MEMBER 1.0 3.0 X 0 0 0 1244064 49976 163352 8 false true false SENTIEN BIOTECHNOLOGIES INC 99 HAYDEN AVE BLDG E STE 140 LEXINGTON MA 02421 PROF SERVICES 122752 CHARLES RIVER LABS PO BOX 27812 NEW YORK NY 100877812 TESTING SERVICES 119895 2 0 BIOMANUFACTURING SERVICE FEES 621991 4996591 4996591 4996591 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PURCHASE REBATES 621300 15818 15818 15818 5012409 5012409 0 0 0 0 494594 494594 0 2317561 2317561 125130 125130 312282 312282 185977 185977 0 0 0 0 0 0 186378 186378 49147 49147 233794 233794 17814 17814 0 844342 844342 78737 78737 0 7778 7778 190802 190802 0 1539694 1539694 4313 4313 SUPPORT & ADMINISTRATIVE FEE 4332581 4332581 TESTING EXPENSES & SUPPLIES 2172559 2172559 EQUIPMENT MAINTENANCE 347786 347786 CUSTOMER FREIGHT 177714 177714 102040 102040 13721023 9384129 4336894 0 125222 138260 0 0 0 0 2625585 2067816 0 0 0 0 0 0 959033 1064171 116268 121668 16893998 4276155 12810869 12617843 0 0 0 0 0 0 0 0 0 5817384 16636977 21827142 2865268 2614994 0 0 0 0 0 0 0 0 0 0 7473147 5836922 0 0 51656 6341139 10390071 14793055 X 6246906 7034087 0 0 6246906 7034087 16636977 21827142 X -8708614 9495795 X false true X true false X 569065 369448 245835 0 0 1184348 9177173 15464443 11388400 3990807 5012409 45033232 0 0 0 9746238 15833891 11634235 3990807 5012409 46217580 0 0 0 46217580 132514 210963 343477 0 132514 210963 343477 0 0 9878752 16044854 11634235 3990807 5012409 46561057 0.99262 0.99161 0.00738 0.00839 X 13721023 13721023 836051 209013 1000000 1000000 681936 836051 3517987 5276981 30043 0 0 0 30043 250000 250000 170484 209013 879497 1319246 0 0 0 0 0 612187 194411 417776 3946552 700535 3246017 11406195 3330964 8075231 929064 50245 878819 12617843 INTERCOMPANY RECEIVABLE 293281 RIGHT-OF-USE ASSETS - LEASES 5524103 5817384 0 OPERATING LEASE LIABILITIES 6341139 6341139 5012409 5012409 5012409 13721023 13721023 13721023 SCHEDULE D, PART X, LINE 2 ASC 740 FOOTNOTE: MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. false false false false false true true false false BECKY CAP SVP COO, GENCURE (THRU 09/22) 206024 49397 29590 0 1945 579 10756 2652 1419 403 249734 53031 CHRISTIE ELAINE MALONE DIRECTOR, BUSINESS DEVELOPMENT 154492 10000 2293 10425 19397 196607 MARI LANE SALMI SR. DIRECTOR PROCESS DEV & CEL 130161 6244 2063 3835 31367 173670 AMANDA THERESE WHITELONIS DIRECTOR, PROGRAM MANAGEMENT 140238 5612 1276 8902 8835 164863 ROGELIO ZAMILPA SR. DIRECTOR, MFG SCIENCES 169506 18541 2142 11693 17011 218893 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS 218795 6050 3882 8818 19295 256840 SCHEDULE J, PART I, LINE 3 METHOD USED TO ESTABLISH TOP MANAGEMENT OFFICIAL COMPENSATION: THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS THAT USED ONE OR MORE OF THE METHODS LISTED IN SCHEDULE J, PART I, LINE 3 TO ESTABLISH THE TOP MANAGEMENT OFFICIAL'S COMPENSATION. SCHEDULE J, PART I, LINE 6A COMPENSATION CONTINGENT ON ORGANIZATION'S EARNINGS: THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS OF DETERMINING THE COMPENSATION CONTINGENT ON THE ORGANIZATION'S EARNINGS. THE PROCESS IS DISCLOSED ON THEIR FORM 990. FORM 990, PART I, LINE 1 & PART III, LINE 4A DESCRIPTION OF ORGANIZATION'S MISSION OR MOST SIGNIFICANT ACTIVITIES: GenCure enables progress in the field of advanced therapies by offering process and analytical development, cGMP manufacturing, in-process and release testing, while leveraging a unified quality management system. We partner with our customers with the end goal of clinical development and commercialization in mind. In 2022, market activity increased GenCure's manufacturing demand for customers in Phase 1 & 2. In order to meet the demand of the customers in a later regulatory phase, the need to shift into a commercial manufacturing center became apparent. This led to a retro-fit of our cleanrooms to ensure compliance and allow for the facility to support concurrent, multiproduct, manufacturing events and genetically modified cells. In addition, GenCure has expanded technical capabilities, designed to support advanced therapy manufacturing, including cell isolation technology. Internally, GenCure has successfully implemented electronic batch records using the MasterControl platform. The added automation of the electronic batch record has demonstrated improved efficiency with regards to record completion, review, and approval, while maintaining a high level of compliance for document control. Regarding workforce development, the GenCure team expanded to include personnel from the local area through a partnership with the San Antonio for Growth on the Eastside organization. The GenCure team has increased their community support by actively participating in the Step into Stem program sponsored by Texas Research and Technology Foundation which provides mentoring to local students to increase awareness for STEM-based careers. FORM 990, PART VI, SECTION A, LINE 6 LIST OF MEMBERS AND STOCKHOLDERS: BIOBRIDGE GLOBAL IS THE SOLE MEMBER OF THE CORPORATION. FORM 990, PART VI, SECTION A, LINE 8A DOCUMENTATION OF MEETINGS OR WRITTEN ACTIONS BY THE GOVERNING BODY: MEETINGS HELD AND WRITTEN ACTIONS UNDERTAKEN WERE DOCUMENTED IN THE MINUTES OF THE MEETINGS OF BIOBRIDGE GLOBAL'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B PROCESS TO REVIEW THE FORM 990: THE ORGANIZATION ENGAGES AN OUTSIDE ACCOUNTING FIRM TO PREPARE THE FORM 990. ONCE PREPARED, THE RETURN IS REVIEWED BY THE FINANCIAL MANAGEMENT STAFF FROM BIOBRIDGE GLOBAL, A RELATED ORGANIZATION. A COPY OF THE FORM 990 IS PROVIDED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C COMPLIANCE WITH CONFLICT OF INTEREST POLICY: A COPY OF THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED ANNUALLY TO ALL OFFICERS, KEY EMPLOYEES AND BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL. IN ADDITION, QUESTIONNAIRES ARE GIVEN OUT ON AN ANNUAL BASIS TO ALL OFFICERS, KEY EMPLOYEES AND BOARD OF DIRECTORS WHICH COVER BUSINESS AND FAMILY RELATIONSHIPS AND VARIOUS ACTIVITIES THAT HAVE OCCURRED OVER THE COURSE OF THE YEAR. EVERY ATTEMPT IS MADE TO ENSURE THAT ALL FORMS ARE RETURNED. INDIVIDUALS WHO FAIL TO RETURN THE REQUESTED FORMS OR PROVIDE INCOMPLETE INFORMATION ARE CONTACTED BY THE ORGANIZATION. IN THE EVENT OF A CONFLICT OF INTEREST, THE MEMBER SUBJECT TO THE CONFLICT OF INTEREST MUST LEAVE THE DISCUSSION AND VOTING ON A TRANSACTION OR ARRANGEMENT THAT RESULTS IN A CONFLICT OF INTEREST. A COMMITTEE OF NON-INTERESTED REPRESENTATIVES SHALL BE APPOINTED TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. THE PARTY WITH A CONFLICT OF INTEREST IS NOT PERMITTED TO ADVOCATE TO OTHER REPRESENTATIVES PRIOR TO THE VOTE. THE COMMITTEE IS RESPONSIBLE FOR EXERCISING DUE DILIGENCE IN DETERMINING THAT THE TRANSACTION IS NOT MORE MATERIALLY ADVANTAGEOUS THAN A DEAL WITH A NON-INTERESTED TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15A REVIEW OF CEO/TOP MANAGEMENT COMPENSATION: IN DETERMINING THE TOP MANAGEMENT OFFICIAL'S COMPENSATION, THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING THE TOP MANAGEMENT COMPENSATION IS DISCLOSED ON THEIR FORM 990. FORM 990, PART VI, SECTION B, LINE 15B REVIEW OF OTHER OFFICER'S COMPENSATION: THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING OTHER OFFICER'S COMPENSATION IS DISCLOSED ON THEIR FORM 990. FORM 990, PART VI, SECTION C, LINE 19 HOW DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC: ANY DOCUMENTS SUBJECT TO OPEN RECORD REQUIREMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS OR FUND BALANCES: EQUITY TRANSFER BETWEEN RELATED ORGANIZATIONS $ 9,495,795 SOUTH TEXAS BLOOD & TISSUE CENTER 6211 IH 10 WEST SAN ANTONIO TX 78201 237379332 BLOOD BANK TX 501(C)(3) 10 SEE PART VII true BIOBRIDGE GLOBAL 6211 IH 10 WEST SAN ANTONIO TX 78201 454765222 SUPPORT ORG. TX 501(C)(3) 12 TYPE II NA false THE BLOOD & TISSUE CENTER FOUNDATION 6211 IH 10 WEST SAN ANTONIO TX 78201 431970952 SUPPORT ORG. TX 501(C)(3) 12 TYPE I SEE PART VII true QUALTEX LABORATORIES 6211 IH 10 WEST SAN ANTONIO TX 78201 208429619 TEST PUB SFTY AZ 501(C)(3) 11 SEE PART VII true false false false false true false false false false false false false true true true true true true true SOUTH TEXAS BLOOD & TISSUE CENTER S 3115573 BOOK COST QUALTEX LABORATORIES S 984263 BOOK COST QUALTEX LABORATORIES M 574605 BOOK COST THE BLOOD & TISSUE CENTER FOUNDATION S 109456 BOOK COST SCHEDULE R, PART II, COLUMN F - DIRECT CONTROLLING ENTITY THE ORGANIZATIONS SPECIFIED ARE ALL CONTROLLED BY BIOBRIDGE GLOBAL.